Filter results

Skin Burn Extensive clinical trials

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

View clinical trials related to Skin Burn Extensive.

Filter by:

Completed
Page 1

NCT ID: NCT01421537 Completed - Skin Burn Extensive Clinical Trials

Evaluation Of Enoxaparin Pharmacokinetic For Thromboprophylaxis In Burn Care Patients

Start date: January 2011
Phase:
Study type: Observational

OVERVIEW: - Thromboembolisms represent a serious and feared complication in hospitalized patients. - Several factors make the ICU patient population at increased risk of venous thromboembolism. - A high incidence of thromboembolic events is starting to emerge from recent medical literature in the burn patient. - Actual guidelines for thromboprophylaxis in burn care patients are based on multiple non-burn patient trials. - Burn patient physiology is radically different than that of general ward hospitalized patients - Since the actual chemical thromboprophylaxis have not been evaluated in the burn patient, it is of interest to assess their efficacy in patients with severe burns. - Hence, the pharmacokinetic characterization of heparins (a well accepted mode of thromboprophylaxis) in burn patients could guide future quality of care for this subclass of patients. Our proposal is based on the conviction that anti-Xa activity of low-molecular-weight heparins in the burn patients do not correlate with levels described to prevent thromboembolic events in the general hospitalized population. The investigators aim to: 1. To evaluate pharmacokinetics and pharmacodynamics of low-molecular-weight heparins (enoxaparin), with anti-Xa levels in severely burned patients receiving thromboprophylaxis. 2. To determine the correlation between antithrombotic activity of heparins and the different metabolic phases of the thermally injured patient.